<DOC>
	<DOCNO>NCT02482324</DOCNO>
	<brief_summary>This open-labeled , cross-over design , pharmacokinetic study , determine pharmacokinetics ALZT-OP1 ( combination drug therapy ) designate ALZT-OP1a ALZT-OP1b , plasma CSF , follow co-administration active compound , healthy volunteer , age 55-75 , good general health .</brief_summary>
	<brief_title>Phase 1 Study ALZT-OP1 Combination Therapy Normal Healthy Volunteers</brief_title>
	<detailed_description>This open-labeled , cross-over design , pharmacokinetic study , 24 subject randomly assign receive treatment regimen A-B B-A two consecutive day dose . Two dose group plan study : - Group 1 ( n=12 ) - Group 2 ( n=12 ) Each group admit Phase I Unit even dose initiate dose next morning 2-days consecutive treatment ( A-B , B-A ) . Both group undergo identical study related procedure , except subject consent CSF collection Day 1 dosing . Dose regimen A consist single inhaled oral dose ALZT-OP1a via dry powder inhaler + single oral tablet dose ALZT-OP1b . Dose regimen B consist two oral inhaled dos ALZT-OP1a , 2 minute apart , via dry powder inhaler + two oral tablet dose ALZT-OP1b . Plasma Collection , All Subjects ( n=24 ) 1 mL blood sample collect T : 0 , 5 , 10 , 15 , 30 , 1 hr , 2 hr , 4 hr , 6 hour , follow ALZT-OP1 administration ( Days 1 2 ) . CSF Collection , Sub-group ( n=12 ) A sub-group 12 subject consent CSF collection . 1 mL CSF collect T : 0 , 5 min , 30 min , 2 hr , 4 hour , follow ALZT-OP1 administration ( Day 1 ) .</detailed_description>
	<criteria>Provide sign write informed consent ; Age 5575 inclusive ; ECG within normal limit ; Body mass index ( BMI ) ≥ 18 kg/m2 ≤ 30 kg/m2 ; Negative urine drug screen select drug abuse screening ; Negative hepatitis HIV screening ; Good general health , determine medical history , physical examination , clinical laboratory testing ; Willingness stay unit overnight duration study ; Consent CSF collection ( CSF group ) . Current smoker , exsmokers remote history ( &gt; 100 pack/year ) ; Clinically significant medical condition ; History ECG abnormality ; Symptomatic viral infection , suspicion thereof ( include rhinitis ) last 14 day prior dose ; Signs active pulmonary infection pulmonary inflammatory condition , even absence febrile episode , last 14 day ; History presence disease kidney and/or heart , lung , liver , gastrointestinal tract , endocrine organ condition metabolic disease know interfere absorption , distribution , metabolism , excretion drug ; Malignancy , regardless location ; Autoimmune disorder ( limit ) lupus erythematosus , multiple sclerosis , rheumatoid arthritis , sarcoidosis ; Investigational agent prohibit one month prior entry duration trial ; Currently take medication know CYP2C9 inducer ( i.e . carbamazepine rifampicin ) ; Currently take cromolyn , take cromolyn , within past 30 day ; NSAID use ( product contain ibuprofen study ) ; Aspirin , product contain aspirin , study ; Allergy hypersensitivity cromolyn ( also know Intal® , Nasalcrom® , etc . ) ; Allergy hypersensitivity ibuprofen ( Advil® , Motrin® , Nuprin® , etc . ) aspirin , include StevensJohnson syndrome ; History hypersensitivity allergy drug compound investigation ( cromolyn , ibuprofen , lactose , magnesium stearate ) ; History clinically significant respiratory disorder chronic respiratory disease impair respiratory effort difficulty take inhaled drug ( example : COPD , emphysema ) ; Abnormal pulmonary function test , define protocol : FEV1/FVC &lt; 70 % predict value subject , compare reference value ; AND FEV1 FVC &lt; 70 % predict value compare reference value , indicate moderate severe respiratory obstruction ; Any disease condition , , opinion investigator , would make subject unsuitable study ; Female subject reproductive potential positive pregnancy test ( urine serum ) pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>